Evidence map›Paper›PMID 28257481›Full record

ArticlePloS one2017

Toll-like receptor 2 activation and serum amyloid A regulate smooth muscle cell extracellular matrix.

Stephanie E Seidl, Lawrence G Pessolano, Christopher A Bishop, Michael Best, Celeste B Rich, Phillip J Stone, Barbara M Schreiber

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Serum amyloid A in HFpEF and cardiometabolic diseases.Basic research in cardiology · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Stephanie E SeidlDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Lawrence G PessolanoDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Christopher A BishopDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Michael BestDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Celeste B RichDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Phillip J StoneDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Barbara M SchreiberDepartment of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, United States of America.ORCID http://orcid.org/0000-0001-8560-4249
Boston University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Smooth muscle cells contribute to extracellular matrix remodeling during atherogenesis. De-differentiated, synthetic smooth muscle cells are involved in processes of migration, proliferation and changes in expression of extracellular matrix components, all of which contribute to loss of homeostasis accompanying atherogenesis. Elevated levels of acute phase proteins, including serum amyloid A (SAA), are associated with an increased risk for atherosclerosis. Although infection with periodontal and respiratory pathogens via activation of inflammatory cell Toll-like receptor (TLR)2 has been linked to vascular disease, little is known about smooth muscle cell TLR2 in atherosclerosis. This study addresses the role of SAA and TLR2 activation on smooth muscle cell matrix gene expression and insoluble elastin accumulation. Cultured rat aortic smooth muscle cells were treated with SAA or TLR2 agonists and the effect on expression of matrix metallopeptidase 9 (MMP9) and tropoelastin studied. SAA up-regulated MMP9 expression. Tropoelastin is an MMP9 substrate and decreased tropoelastin levels in SAA-treated cells supported the concept of extracellular matrix remodeling. Interestingly, SAA-induced down-regulation of tropoelastin was not only evident at the protein level but at the level of gene transcription as well. Contributions of proteasomes, nuclear factor κ B and CCAAT/enhancer binding protein β on regulation of MMP9 vs. tropoleastin expression were revealed. Effects on Mmp9 and Eln mRNA expression persisted with long-term SAA treatment, resulting in decreased insoluble elastin accumulation. Interestingly, the SAA effects were TLR2-dependent and TLR2 activation by bacterial ligands also induced MMP9 expression and decreased tropoelastin expression. These data reveal a novel mechanism whereby SAA and/or infection induce changes in vascular elastin consistent with atherosclerosis.

Indexed as

AnimalsAtherosclerosisCell MovementCell ProliferationExtracellular MatrixGene Expression RegulationHumansMatrix Metalloproteinase 9Myocytes, Smooth MuscleRatsRisk FactorsSerum Amyloid A ProteinToll-Like Receptor 2TropoelastinMatrix Metalloproteinase 9MMP9 protein, humanSerum Amyloid A ProteinTLR2 protein, humanToll-Like Receptor 2Tropoelastin

Identifiers

PMID28257481
PMCPMC5336220
OpenAlexW2592171572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.